Tesofensine, beta blocker combination formulation
The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.
1. A pharmaceutical composition comprising
a. a first composition in the form of a tablet core comprising an extended release composition of carvedilol or a pharmaceutically acceptable salt thereof,
b. a second composition comprising tesofensine or a pharmaceutically acceptable salt thereof, wherein said second composition is a first coating applied to the first composition, and
c. a third composition comprising an immediate release composition of carvedilol or a pharmaceutically acceptable salt thereof, wherein the third composition is a second coating applied to the first coating.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable salt of carvedilol is the phosphate, succinate, maleate, sulfate, glutarate, lactate, benzoate, or mandelate salt.
3. The pharmaceutical composition of claim 1 , wherein the tesofensine or pharmaceutically acceptable salt thereof is tesofensine free base, tesofensine citrate salt, or tesofensine tartrate salt.
4. The pharmaceutical composition of claim 1 , wherein the extended release composition comprises cores comprising carvedilol, the cores being coated with a controlled release layer comprising an admixture of:
a. an ethylacrylate/methylmethacrylate copolymer,
b. a surfactant, and
c. sodium stearyl fumarate,
and wherein the controlled release layer has been deposited from a water-containing liquid and the amount of the ethylacrylate/methylmethacrylate copolymer in the film coat is in the range of 80-99.5% (w/w).
5. The pharmaceutical composition of claim 1 , wherein the composition is in the form of a pharmaceutical dosage form.
6. The pharmaceutical composition of claim 5 , wherein the pharmaceutical dosage form is a tablet.
7. The pharmaceutical composition of claim 1 , wherein the first composition comprises 20-100 mg of carvedilol or a pharmaceutically acceptable salt thereof.
8. The pharmaceutical composition of claim 1 , wherein the second composition comprises 0.1-1 mg of tesofensine or a pharmaceutically acceptable salt thereof.
9. The pharmaceutical composition of claim 1 , wherein the third composition comprises 5-25 mg of carvedilol or a pharmaceutically acceptable salt thereof.
10. The pharmaceutical composition of claim 1 , wherein the ratio of extended release carvedilol to immediate release carvedilol is 75-95:25-5.
11. The pharmaceutical composition of claim 1 , wherein the first composition comprises 40-80 mg of carvedilol, the third composition comprises 5-20 mg of carvedilol, and the second composition comprises 0.25-0.75 mg of tesofensine.
12. A pharmaceutical composition comprising
a. a first composition in the form of a tablet core comprising an extended release composition of a beta blocker or a pharmaceutically acceptable salt thereof,
b. a second composition comprising tesofensine or a pharmaceutically acceptable salt thereof, wherein said second composition is a first coating applied to the first composition, and
c. a third composition comprising an immediate release composition of the beta blocker or a pharmaceutically acceptable salt thereof, wherein the third composition is a second coating applied to the first coating.
13. The pharmaceutical composition of claim 12 , wherein the beta blocker is a beta 1-selective beta blocker, a mixed alpha and beta blocker, a non-selective beta blocker, or a beta 2-selective beta blocker.
14. The pharmaceutical composition of claim 12 , wherein the beta blocker is acebutolol, atenolol, betaxolol, bisoprolol, esmolol, landiolol, nebivolol, or a pharmaceutically acceptable salt thereof.
15. The pharmaceutical composition of claim 12 , wherein the beta blocker is celiprolol, labetalol, or a pharmaceutically acceptable salt thereof.
16. The pharmaceutical composition of claim 12 , wherein the beta blocker is alprenolol, amosulalol, bucindolol, carteolol, levobunolol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, or a pharmaceutically acceptable salt thereof.
17. The pharmaceutical composition of claim 12 , wherein the beta blocker is butaxamine or a pharmaceutically acceptable salt thereof.
18. The pharmaceutical composition of claim 12 , wherein the tesofensine or pharmaceutically acceptable salt thereof is tesofensine free base, tesofensine citrate salt, or tesofensine tartrate salt.
19. The pharmaceutical composition of claim 12 , wherein the extended release composition comprises cores comprising the beta blocker or a pharmaceutically acceptable salt thereof, the cores being coated with a controlled release layer comprising an admixture of:
a. an ethylacrylate/methylmethacrylate copolymer,
b. a surfactant, and
c. sodium stearyl fumarate,
and wherein the controlled release layer has been deposited from a water-containing liquid and the amount of the ethylacrylate/methylmethacrylate copolymer in the film coat is in the range of 80-99.5% (w/w).
20. The pharmaceutical composition of claim 12 , wherein the composition is in the form of a pharmaceutical dosage form.
21. The pharmaceutical composition of claim 20 , wherein the pharmaceutical dosage form is a tablet.
22. The pharmaceutical composition of claim 12 , wherein the first composition comprises 20-200 mg of the beta blocker or a pharmaceutically acceptable salt thereof.
23. The pharmaceutical composition of claim 12 , wherein the second composition comprises 0.1-1 mg of tesofensine or a pharmaceutically acceptable salt thereof.
24. The pharmaceutical composition of claim 12 , wherein the third composition comprises 5-100 mg of the beta blocker or a pharmaceutically acceptable salt thereof.
25. The pharmaceutical composition of claim 12 , wherein the ratio of extended release beta blocker to immediate release beta blocker is 75-95:25-5.
26. The pharmaceutical composition of claim 12 , wherein the first composition comprises 50-200 mg of the beta blocker or a pharmaceutically acceptable salt thereof, the third composition comprises 5-50 mg of the beta blocker or a pharmaceutically acceptable salt thereof, and the second composition comprises 0.1-1.5 mg of tesofensine.